CT-STARWOOD-HOTELS
29.4.2016 12:11:17 CEST | Business Wire | Press release
Tribute Portfolio, a collection of independent hotels and resorts from Starwood Hotels & Resorts Worldwide, Inc. (NYSE: HOT), today announced three new signings, bringing the brand’s footprint to 20 properties worldwide, exactly double the original growth projection for its first year. Continuing to global expansion with its first-ever property in China and continuing to expand in Florida with signings in Tampa and Sarasota, Tribute Portfolio maintains its steadfast position as having the fastest takeoff of any Starwood brand, ever, while also celebrating its individuality through innovative social media and brand partnership strategies. With a long runway to grow, Tribute Portfolio continues to add exceptional properties around the globe that offer guests and owners the ability to “Stay Independent.”
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160429005399/en/
From the Bustling City of Shanghai to the Sunny Coast of Florida
With momentum steadily building for the one year old brand, Tribute Portfolio once again answers consumer demand with the addition of three properties in Shanghai, Sarasota and Tampa. When surveying Starwood Preferred Guest® (SPG) Members, the brand found that 62% would be very interested in staying at a Tribute Portfolio hotel in Shanghai. Answering this call, Tribute Portfolio will expand its footprint in Asia by adding a property in the cosmopolitan Chinese city. Members also told the brand that beach destinations remain at the top of their list, particularly in Florida. As a result, the brand will open an additional two new properties in the Sunshine State: a 323-room hotel in Tampa, and The Sarasota Modern, a Tribute Portfolio Hotel, in Sarasota.
Giving Guests -- And Owners -- What They Want
From boutique resorts to urban destination properties, Tribute Portfolio gives guests access to outstanding upper upscale hotels with an independent spirit, all while benefitting from the award-winning SPG® program. Built and fueled by consumer preferences, Tribute Portfolio carves out its distinction in the category through its close collaboration with the SPG community.
“The independent hotel segment has continued to grow exponentially, with consumers increasingly desiring travel to hotels and resorts that don’t fall under a cookie-cutter brand,” said Dave Marr, Global Brand Leader, Tribute Portfolio. “This trend, coupled with the strength and support of our owner and developer community, has contributed to the meteoric growth of the brand and its continued success as we enter our second year.”
Tribute Portfolio debuted in April 2015 with its first hotel, the Royal Palm South Beach Miami, and has since opened eight additional properties: the Great Northern Hotel in London, UK; The Kiroro Resort in Hokkaido, Japan; The Hermitage in Jakarta, Indonesia; the SLS Las Vegas in Las Vegas, NV; The Riviera Palm Springs in Palm Springs, CA; Avenue of the Arts in Costa Mesa, CA; and Le Dokhan’s and Le Metropolitan, both in Paris. Future locations include Coral Gables, FL; Fort Lauderdale, FL; Tampa, FL; Sarasota, FL; Asheville, NC; Nashville, Tennessee; Savannah, GA; Charleston, SC; Denver, CO; Shanghai, China; and Quebec City, Canada.
With flexibility and individuality at its core, Tribute Portfolio has also struck a chord with the owner/developer community, enabling them to maintain their independent spirit, while benefiting from Starwood's powerful distribution, loyalty and sales platforms.
"The rapid rate of growth that Tribute Portfolio has achieved comes as no surprise, combining Starwood’s robust sales, marketing and loyalty programs with the flair and individualism of the independent boutique hotelier,” said Jeremy Robson, Owner-Operator, Great Northern Hotel, London. “I am delighted that Great Northern Hotel is now part of the Tribute Portfolio franchise, and the abundant positive feedback we get from our customers indicates they feel the same. I expect the brand’s global expansion to continue accelerating way beyond the most optimistic of forecasts.”
Reaching Socially Connected, Independent-Minded Travelers
Shifting focus from being the expert on the destination, Tribute Portfolio instead elevates the notion that guests seek out independent hotels because the hotels themselves can be the destination. To capture this, each Tribute Portfolio property features a noteworthy selection of #independentmoments : distinct design details and experiences that illustrate what guests love about “staying independent.” In addition, Tribute Portfolio is the first hotel brand to partner with consumer shopping service, LIKEtoKNOW.it , enabling travelers to translate their wanderlust into room bookings at two of the Tribute Portfolio brand’s newest hotels – Le Metropolitan and Le Dokhan’s – directly by “liking” a photo on Instagram. Finally, the brand also launched a new partnership with Pitchfork that will bring unique pop-up music activations to several Tribute Portfolio properties worldwide, exposing guests to emerging artists and established pioneers who apply a true independent mindset to their musical craft, regardless of genre.
For more information, please visit www.tributeportfolio.com .
# # #
About Tribute Portfolio
Launched
in April 2015 as Starwood’s 10th brand and second collection of
independent hotels, Tribute Portfolio is comprised of exceptional
independent hotels around the globe, offering guests and owners the
ability to “Stay Independent.” From boutique resorts to urban
destination properties, guests can enjoy access to outstanding upper
upscale hotels with an indie spirit while benefitting from the
award-winning Starwood Preferred Guest (SPG) program. For more
information on Tribute Portfolio, please visit www.tributeportfolio.com
.
Follow along to Stay Independent: @TributePortfolio
on Instagram, @TributePRTFLO
on Twitter, tumblr.com/TributePortfolio
and www.facebook.com/TributePortfolio
.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005399/en/
Contact:
Starwood Hotels & Resorts
Media Contacts
Julien
Guitard, +32 2 204 5160
Associate Director Communications – Europe,
Africa & Middle East
Julien.Guitard@starwoodhotels.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
